Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) EBIT (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of EBIT data on record, last reported at -$5.9 million in Q3 2025.

  • For Q3 2025, EBIT rose 17.22% year-over-year to -$5.9 million; the TTM value through Sep 2025 reached -$24.2 million, up 16.27%, while the annual FY2024 figure was -$26.6 million, 10.09% up from the prior year.
  • EBIT reached -$5.9 million in Q3 2025 per MBRX's latest filing, down from -$5.7 million in the prior quarter.
  • Across five years, EBIT topped out at -$5.2 million in Q4 2021 and bottomed at -$9.1 million in Q3 2022.
  • Average EBIT over 5 years is -$6.7 million, with a median of -$6.4 million recorded in 2023.
  • Peak YoY movement for EBIT: crashed 48.96% in 2021, then skyrocketed 34.53% in 2023.
  • A 5-year view of EBIT shows it stood at -$5.2 million in 2021, then tumbled by 35.38% to -$7.0 million in 2022, then decreased by 26.55% to -$8.9 million in 2023, then grew by 25.52% to -$6.6 million in 2024, then rose by 11.09% to -$5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$5.9 million in Q3 2025, -$5.7 million in Q2 2025, and -$5.9 million in Q1 2025.